BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11741790)

  • 1. omega-(Imidazol-4-yl)alkane-1-sulfonamides: a new series of potent histamine H(3) receptor antagonists.
    Tozer MJ; Buck IM; Cooke T; Kalindjian SB; Pether MJ; Steel KI
    Bioorg Med Chem; 2002 Feb; 10(2):425-32. PubMed ID: 11741790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel histamine H3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold.
    Vaccaro WD; Sher R; Berlin M; Shih NY; Aslanian R; Schwerdt JH; McCormick KD; Piwinski JJ; West RE; Anthes JC; Williams SM; Wu RL; She HS; Rivelli MA; Mutter JC; Corboz MR; Hey JA; Favreau L
    Bioorg Med Chem Lett; 2006 Jan; 16(2):395-9. PubMed ID: 16246552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 2-(4-alkylpiperazin-1-yl)quinolines as a new class of imidazole-free histamine H3 receptor antagonists.
    Zaragoza F; Stephensen H; Peschke B; Rimvall K
    J Med Chem; 2005 Jan; 48(1):306-11. PubMed ID: 15634025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and histamine H3 receptor activity of 4-(n-alkyl)-1H-imidazoles and 4-(omega-phenylalkyl)-1H-imidazoles.
    De Esch IJ; Gaffar A; Menge WM; Timmerman H
    Bioorg Med Chem; 1999 Dec; 7(12):3003-9. PubMed ID: 10658607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of CYP450 inhibition in the 4-[(1H-imidazol-4-yl)methyl]piperidine series of histamine H3 receptor antagonists.
    Berlin M; Ting PC; Vaccaro WD; Aslanian R; McCormick KD; Lee JF; Albanese MM; Mutahi MW; Piwinski JJ; Shih NY; Duguma L; Solomon DM; Zhou W; Sher R; Favreau L; Bryant M; Korfmacher WA; Nardo C; West RE; Anthes JC; Williams SM; Wu RL; Susan She H; Rivelli MA; Corboz MR; Hey JA
    Bioorg Med Chem Lett; 2006 Feb; 16(4):989-94. PubMed ID: 16297617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of FUB 181, a selective histamine H3-receptor antagonist of high oral in vivo potency with 4-(omega-(arylalkyloxy)alkyl)-1H-imidazole structure.
    Stark H; Hüls A; Ligneau X; Purand K; Pertz H; Arrang JM; Schwartz JC; Schunack W
    Arch Pharm (Weinheim); 1998 Jun; 331(6):211-8. PubMed ID: 9713254
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 4-[(1H-imidazol-4-yl) methyl] benzamidines and benzylamidines: novel antagonists of the histamine H3 receptor.
    Aslanian R; Brown JE; Shih NY; wa Mutahi M; Green MJ; She S; Del Prado M; West R; Hey J
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2263-8. PubMed ID: 9873525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and in vitro pharmacology of a series of new chiral histamine H3-receptor ligands: 2-(R and S)-Amino-3-(1H-imidazol-4(5)-yl)propyl ether derivatives.
    Kovalainen JT; Christiaans JA; Kotisaari S; Laitinen JT; Männistö PT; Tuomisto L; Gynther J
    J Med Chem; 1999 Apr; 42(7):1193-202. PubMed ID: 10197963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New histamine H(3)-receptor ligands of the proxifan series: imoproxifan and other selective antagonists with high oral in vivo potency.
    Sasse A; Sadek B; Ligneau X; Elz S; Pertz HH; Luger P; Ganellin CR; Arrang JM; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2000 Aug; 43(17):3335-43. PubMed ID: 10966752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 4-Alkynylphenyl imidazolylpropyl ethers as selective histamine H3-receptor antagonists with high oral central nervous system activity.
    Krause M; Ligneau X; Stark H; Garbarg M; Schwartz JC; Schunack W
    J Med Chem; 1998 Oct; 41(21):4171-6. PubMed ID: 9767653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 4-(omega-(alkyloxy)alkyl)-1H-imidazole derivatives as histamine H(3) receptor antagonists/agonists.
    Meier G; Krause M; Hüls A; Ligneau X; Pertz HH; Arrang JM; Ganellin CR; Schwartz JC; Schunack W; Stark H
    J Med Chem; 2004 May; 47(10):2678-87. PubMed ID: 15115409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Search for novel leads for histamine H3-receptor antagonists: oxygen-containing derivatives.
    Stark H; Hüls A; Ligneau X; Arrang JM; Schwartz JC; Schunack W
    Pharmazie; 1997 Jul; 52(7):495-500. PubMed ID: 9266588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a pharmacophore model for histamine H3 receptor antagonists, using the newly developed molecular modeling program SLATE.
    De Esch IJ; Mills JE; Perkins TD; Romeo G; Hoffmann M; Wieland K; Leurs R; Menge WM; Nederkoorn PH; Dean PM; Timmerman H
    J Med Chem; 2001 May; 44(11):1666-74. PubMed ID: 11356102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel histamine H(3)-receptor antagonists with carbonyl-substituted 4-(3-(phenoxy)propyl)-1H-imidazole structures like ciproxifan and related compounds.
    Stark H; Sadek B; Krause M; Hüls A; Ligneau X; Ganellin CR; Arrang JM; Schwartz JC; Schunack W
    J Med Chem; 2000 Oct; 43(21):3987-94. PubMed ID: 11052804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of chiral N-alkylcarbamates as new leads for potent and selective H3-receptor antagonists: synthesis, capillary electrophoresis, and in vitro and oral in vivo activity.
    Sasse A; Kiec-Kononowicz K; Stark H; Motyl M; Reidemeister S; Ganellin CR; Ligneau X; Schwartz JC; Schunack W
    J Med Chem; 1999 Feb; 42(4):593-600. PubMed ID: 10052966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel H3 receptor antagonists. Sulfonamide homologs of histamine.
    Wolin R; Connolly M; Afonso A; Hey JA; She H; Rivelli MA; Willams SM; West RE
    Bioorg Med Chem Lett; 1998 Aug; 8(16):2157-62. PubMed ID: 9873505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
    Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
    J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and pharmacological characterization of a series of new 1H-4-substituted-imidazoyl histamine H3 receptor ligands.
    Yates SL; Phillips JG; Gregory R; Pawlowski GP; Fadnis L; Khan MA; Ali SM; Tedford CE
    J Pharmacol Exp Ther; 1999 May; 289(2):1151-9. PubMed ID: 10215699
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of imidazole replacement in different structural classes of histamine H(3)-receptor antagonists.
    Meier G; Apelt J; Reichert U; Grassmann S; Ligneau X; Elz S; Leurquin F; Ganellin CR; Schwartz JC; Schunack W; Stark H
    Eur J Pharm Sci; 2001 Jun; 13(3):249-59. PubMed ID: 11384847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel, orally bioavailable histamine H(3) receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template.
    Aslanian R; Mutahi MW; Shih NY; McCormick KD; Piwinski JJ; Ting PC; Albanese MM; Berlin MY; Zhu X; Wong SC; Rosenblum SB; Jiang Y; West R; She S; Williams SM; Bryant M; Hey JA
    Bioorg Med Chem Lett; 2002 Mar; 12(6):937-41. PubMed ID: 11958998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.